Vutrisiran appears to effectively conserve functional capacity and quality of life (QOL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), according to a recently published study in the Journal of the American College of Cardiology.
“The present analysis expands on the results from secondary endpoints in HELIOS-B, which have been presented previously, demonstrating significant benefit with vutrisiran compared with placebo with regard to preservation of function and QOL,” the authors wrote.
The HELIOS-B clinical trial revealed that vutrisiran has a positive effect on cardiovascular events and mortality in patients with ATTR-CM. Based on these results, vutrisiran was recently approved by the FDA for the treatment of ATTR-CM.
Building on this research, the study’s authors aimed to determine if vutrisiran also improved QOL and functional capacity in patients with the disease.
Read more about ATTR-CM therapies
To this end, researchers compared the results of the six-minute walking test (6MWT) and Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) between patients receiving vutrisiran and patients receiving placebo.
The study included patients from over 80 healthcare centers in 26 countries. Results showed that most patients receiving vutrisiran improved or maintained their 6MWT score, with 68% achieving 35 meters compared to 51% on placebo. The majority of patients who improved their initial score were taking vutrisiran.
Similarly, the KCCQ-OS showed that patients on vutrisiran were more likely to maintain or improve their baseline results regarding quality of life after 30 months of treatment. Approximately 73% of patients on vutrisiran had a KCCQ-OS over 10 compared to 51% of those on placebo.
The coherence between KCCQ-OS and 6MWT results further underscore the benefits of reducing circulating TTR levels through drugs like tafamidis or vutrisiran. The findings suggest that vutrisiran not only reduces mortality but also improves quality of life.
“In this analysis of HELIOS-B, vutrisiran maintained or improved functional capacity, health status, and QOL in a greater proportion of patients with ATTR-CM versus placebo and benefits were consistent across multiple cutoff values,” the authors concluded. “Additionally, change from baseline analyses demonstrated consistent benefits with vutrisiran compared with placebo across all prespecified subgroups,”
Sign up here to get the latest news, perspectives, and information about ATTR-CM sent directly to your inbox. Registration is free and only takes a minute.
